• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 08, 2023 at 10:22: AM
via Even as Novartis CEO Vas Narasimhan works through a companywide restructuring, the chief exec saw his pay decline substantially in 2022 thanks to demerits on the company’s shareholder return scorecard.

article source
 




Top Bottom
Back
Quote